secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001683168-23-007671
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign Q3 revenue up 17% to $12.4M; net income $1.1M; pharma revenue +142%
---------------------------------------------------------------------------

- Q3 total revenues $12.4M (+17% YoY); net income $1.1M, diluted EPS $0.02.
- Adjusted EBITDA $2.3M (+22% YoY); plasma revenue +13%, pharma patient affordability revenue +142%.
- Added 19 new plasma centers (462 total); avg revenue per plasma center per month $8,102 (+7.8% YoY).
- Exited quarter with $9.9M unrestricted cash, zero debt; repurchased 75k shares for $150k.
- FY2023 guidance reaffirmed: revenue $44-46M, Adj. EBITDA $6-7.5M; Q4 growth expected slightly above 17%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316823007671/0001683168-23-007671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316823007671/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-007671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer